JP7442095B2 - ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法 - Google Patents

ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法 Download PDF

Info

Publication number
JP7442095B2
JP7442095B2 JP2020502652A JP2020502652A JP7442095B2 JP 7442095 B2 JP7442095 B2 JP 7442095B2 JP 2020502652 A JP2020502652 A JP 2020502652A JP 2020502652 A JP2020502652 A JP 2020502652A JP 7442095 B2 JP7442095 B2 JP 7442095B2
Authority
JP
Japan
Prior art keywords
composition
enantiomer
subject
treatment
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527583A (ja
JP2020527583A5 (cg-RX-API-DMAC7.html
Inventor
エリック・ヴァーディン
ジョン・シー・ニューマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2020527583A publication Critical patent/JP2020527583A/ja
Publication of JP2020527583A5 publication Critical patent/JP2020527583A5/ja
Application granted granted Critical
Publication of JP7442095B2 publication Critical patent/JP7442095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2020502652A 2017-07-21 2018-07-19 ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法 Active JP7442095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535754P 2017-07-21 2017-07-21
US62/535,754 2017-07-21
PCT/US2018/042948 WO2019018683A1 (en) 2017-07-21 2018-07-19 BETA-HYDROXYBUTYRATE AND BUTANEDIOL ENANTIOMERS AND METHODS OF USE THEREOF

Publications (3)

Publication Number Publication Date
JP2020527583A JP2020527583A (ja) 2020-09-10
JP2020527583A5 JP2020527583A5 (cg-RX-API-DMAC7.html) 2021-09-09
JP7442095B2 true JP7442095B2 (ja) 2024-03-04

Family

ID=65015819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502652A Active JP7442095B2 (ja) 2017-07-21 2018-07-19 ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法

Country Status (11)

Country Link
US (1) US11773051B2 (cg-RX-API-DMAC7.html)
EP (1) EP3654963A4 (cg-RX-API-DMAC7.html)
JP (1) JP7442095B2 (cg-RX-API-DMAC7.html)
KR (1) KR102795284B1 (cg-RX-API-DMAC7.html)
CN (1) CN111050764A (cg-RX-API-DMAC7.html)
AU (1) AU2018304380B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020001285A2 (cg-RX-API-DMAC7.html)
CA (1) CA3070453A1 (cg-RX-API-DMAC7.html)
IL (1) IL272173B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020000734A (cg-RX-API-DMAC7.html)
WO (1) WO2019018683A1 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10245243B1 (en) * 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
MX385367B (es) 2016-06-07 2025-03-18 The J David Gladstone Inst Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
EP3654963A4 (en) 2017-07-21 2021-04-14 Buck Institute for Research on Aging BETA-HYDROXYBUTYRATE AND BUTANEDIOL S ENANTIOMERS AND THEIR METHODS OF USE
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12037317B2 (en) 2018-01-25 2024-07-16 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
CN114025752A (zh) * 2019-02-11 2022-02-08 阿克塞斯全球科学有限责任公司 富含R-对映体的非外消旋β-羟基丁酸根化合物和组合物以及使用方法
AU2020221569B2 (en) * 2019-02-11 2025-06-26 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
WO2020167693A1 (en) * 2019-02-11 2020-08-20 Access Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with s-enantiomer
CN109806251A (zh) * 2019-03-04 2019-05-28 清华大学 3-羟基丁酸及其衍生物在制备抗动脉粥样硬化的产品中的应用
EP3937920B1 (en) 2019-03-14 2025-07-09 The Regents of the University of California Compositions comprising beta-hydroxybutyrate and citrate for supporting renal health
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
WO2022012767A1 (de) * 2020-07-13 2022-01-20 Ioi Oleo Gmbh Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren
US20240228422A1 (en) * 2020-07-13 2024-07-11 Ioi Oleo Gmbh Process for preparing oxobutanol esters of polymeric carboxylic acids
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN112341542B (zh) * 2021-01-08 2021-05-14 清华大学 一种3-羟基丁酰化修饰蛋白质药物及其制备方法和应用
US20220249497A1 (en) * 2021-02-05 2022-08-11 Health Via Modern Nutrition, Inc. Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance
US20240342121A1 (en) * 2021-07-09 2024-10-17 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
US20250282707A1 (en) * 2022-04-29 2025-09-11 Buck Institute For Research On Aging Novel ketone ester compounds
EP4566598A1 (en) * 2023-12-04 2025-06-11 ZoSaLa Pharma, Inc Compositions providing sglt2i and bhb activity and methods of use to treat human disease
WO2025166164A1 (en) 2024-02-02 2025-08-07 Selah Therapeutics Limited DL- AND L-β-HYDROXYBUTYRATE AND METHODS OF USE THEREOF

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120300A1 (en) 2009-04-16 2010-10-21 Isis Innovation Limited Process for the preparation of (3r)-hydr0xybutyl (3r) -hydroxybutyrate by enzymatic enantioselective reduction employing lactobacillus brevis alcohol dehydrogenase
JP2012500264A (ja) 2008-08-21 2012-01-05 アイシス イノヴェイション リミテッド ヒドロキシ酪酸エステル及びその医学的使用
JP2013520454A (ja) 2010-02-22 2013-06-06 ティーデルタエス リミテッド 栄養組成物
WO2016123229A1 (en) 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders
WO2017011294A1 (en) 2015-07-10 2017-01-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone esters, and other ketogenic sources
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS42663Y1 (cg-RX-API-DMAC7.html) 1966-03-07 1967-01-17
US4263216A (en) 1978-10-20 1981-04-21 The Procter & Gamble Company Diglyceride manufacture
US4436726A (en) 1980-12-15 1984-03-13 Fujisawa Pharmaceutical Co., Ltd. N-Acylpeptide compound, processes for the preparation thereof and the pharmaceutical compositions
BE1001209A3 (fr) 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
US5126373A (en) 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
WO1989010410A1 (fr) 1988-04-27 1989-11-02 Daicel Chemical Industries, Ltd. Procede de preparation de 1,3-butanediol optiquement actif
JP2578658B2 (ja) 1989-02-21 1997-02-05 チッソ株式会社 光学活性化合物及びその製造法
US5008126A (en) 1989-06-27 1991-04-16 Nabisco Brands, Inc. Long chain diol diesters as low calorie fat mimetics
IT1240760B (it) 1990-02-12 1993-12-17 Sigma Tau Ind Farmaceuti Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma.
DK0550779T3 (da) 1992-01-08 1996-02-12 Nestle Sa Kosmetisk eller dermatologisk præparat indeholdende en dioldiester
DE19703471A1 (de) 1997-01-31 1998-08-06 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Butylenglycoldiestern
AU749638B2 (en) 1997-03-17 2002-06-27 Btg International Limited Therapeutic compositions
DE69841002D1 (de) 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
EP1052240B1 (en) 1999-05-11 2003-03-19 Dow AgroSciences LLC Process for the preparation of substituted 3-hydroxybutyrate esters
US20080009467A1 (en) 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
EP1363879A2 (en) 2000-10-11 2003-11-26 Esperion Therapeutics Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
KR20050098244A (ko) 2003-01-10 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 2-데옥시글루코오스를 사용한 암 치료 방법
DK1648952T3 (en) 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
EP1528053A1 (en) 2003-10-31 2005-05-04 Lonza Ag Process for the preparation of (S)- or (R)-4-halo-3-hydroxybutyrates
JP2006063001A (ja) 2004-08-25 2006-03-09 Takasago Internatl Corp 光学活性β−ブチロラクトンの製造方法
US20070203323A1 (en) 2006-02-10 2007-08-30 Gyorgyi Fenyvesi Food compositions comprising biologically-based biodegradable 1,3-propanediol esters
JP5054418B2 (ja) 2007-04-23 2012-10-24 ポーラ化成工業株式会社 クレンジング用の化粧料に好適な皮膚外用剤
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
BR112012027758A2 (pt) 2010-04-28 2016-07-26 Arkema Inc método para melhorar estabilidade de misturas de poliol de poliuretano contendo agente de expansão de olefina halogenada
KR101243240B1 (ko) 2010-07-19 2013-04-04 (주)에이씨티 신규 알킬디올 유도체화합물 및 이를 포함하는 미백용 피부외용제조성물
CN103360243B (zh) 2012-03-31 2015-06-17 中国石油化工股份有限公司 一种1,3-二酰氧基丙烷类化合物的制备方法
WO2013164868A1 (ja) 2012-05-01 2013-11-07 コニカミノルタ株式会社 位相差フィルム、偏光板の製造方法および液晶表示装置
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
CA2905225C (en) 2013-03-14 2021-05-04 Isis Innovation Limited Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
WO2014153416A1 (en) 2013-03-19 2014-09-25 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
WO2014190251A1 (en) 2013-05-24 2014-11-27 Genomatica, Inc. Microorganisms and methods for producing (3r)-hydroxybutyl (3r)-hydroxybutyrate
JP6521967B2 (ja) 2013-08-06 2019-05-29 イマーゴ バイオサイエンシーズ インコーポレイテッド 疾患の治療のためのｋｄｍ１ａ阻害剤
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
MX385367B (es) 2016-06-07 2025-03-18 The J David Gladstone Inst Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
EP3654963A4 (en) 2017-07-21 2021-04-14 Buck Institute for Research on Aging BETA-HYDROXYBUTYRATE AND BUTANEDIOL S ENANTIOMERS AND THEIR METHODS OF USE
US20190262415A1 (en) 2018-02-26 2019-08-29 Ketologie LLC Supplement for inducing and sustaining nutritional ketosis
US20230092706A1 (en) 2020-04-16 2023-03-23 Buck Institute For Research On Aging Treatment of viral pathologies with exogenous ketones

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500264A (ja) 2008-08-21 2012-01-05 アイシス イノヴェイション リミテッド ヒドロキシ酪酸エステル及びその医学的使用
WO2010120300A1 (en) 2009-04-16 2010-10-21 Isis Innovation Limited Process for the preparation of (3r)-hydr0xybutyl (3r) -hydroxybutyrate by enzymatic enantioselective reduction employing lactobacillus brevis alcohol dehydrogenase
JP2013520454A (ja) 2010-02-22 2013-06-06 ティーデルタエス リミテッド 栄養組成物
WO2016123229A1 (en) 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders
WO2017011294A1 (en) 2015-07-10 2017-01-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone esters, and other ketogenic sources
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds

Also Published As

Publication number Publication date
AU2018304380A1 (en) 2020-01-30
KR102795284B1 (ko) 2025-04-11
CN111050764A (zh) 2020-04-21
EP3654963A1 (en) 2020-05-27
CA3070453A1 (en) 2019-01-24
KR20200029547A (ko) 2020-03-18
BR112020001285A2 (pt) 2020-07-28
MX2020000734A (es) 2020-07-29
IL272173A (en) 2020-03-31
US20200140371A1 (en) 2020-05-07
JP2020527583A (ja) 2020-09-10
EP3654963A4 (en) 2021-04-14
IL272173B1 (en) 2025-02-01
US11773051B2 (en) 2023-10-03
AU2018304380B2 (en) 2022-12-15
WO2019018683A1 (en) 2019-01-24
IL272173B2 (en) 2025-06-01

Similar Documents

Publication Publication Date Title
JP7442095B2 (ja) ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法
US20240317671A1 (en) Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
EP2214683B1 (en) Unit dosage for brain health
US20100104621A1 (en) Treating adhd and other diseases involving inflammation
JP5674652B2 (ja) 神経障害の処置のためのアセトアセテートのモノグリセリドおよび誘導体
WO2024166059A1 (en) Compositions comprising n,n-dimethyltryptamine, optionally in combination with n-acylethanolamines and uses thereof
CN119212690A (zh) 包含meai和n-酰基乙醇胺的组合物及其用途
US20240122890A1 (en) Use of exogenous ketone esters to induce weight loss in mammals
US20250282707A1 (en) Novel ketone ester compounds
JP2021536494A (ja) マグネシウム含有製剤及びその使用
WO2024171073A1 (en) Compositions comprising 3,4-methylenedioxymethamphetamine, optionally in combination with n-acylethanolamines, and uses thereof
WO2024171075A1 (en) Compositions comprising ibogaine, optionally in combination with n-acylethanolamines, and uses thereof
US20250161270A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
JP6564868B2 (ja) 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
JP2020055837A (ja) 多発性硬化症の治療のための組成物及び方法
HK1257874B (en) Treatment of alzheimer's disease in a particular patient population
HK1157580A (en) Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240208

R150 Certificate of patent or registration of utility model

Ref document number: 7442095

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150